Human Immunodeficiency Virus Infection-Associated Cardiomyopathy and Heart Failure
Open Access
- 24 October 2022
- journal article
- review article
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 12 (11) , 1760
Abstract
The landscape of human immunodeficiency virus (HIV) epidemiology and treatment is ever-changing, with the widespread and evolving use of antiretroviral therapy (ART). With timely ART, people living with HIV (PLWH) are nearing the life expectancies and the functionality of the general population; nevertheless, the effects of HIV and ART on cardiovascular health remain under investigation. The pathophysiology of HIV-related cardiomyopathy and heart failure (HF) have historically been attributed to systemic inflammation and changes in cardiometabolic function and cardiovascular architecture. Importantly, newer evidence suggests that ART also plays a role in modulating the process of HIV-related cardiomyopathy and HF. In the short term, newer highly active ART (HAART) seems to have cardioprotective effects; however, emerging data on the long-term cardiovascular outcomes of certain HAART medications, i.e., protease inhibitors, raise concerns about the potential adverse effects of these drugs in the clinical course of HIV-related HF. As such, the traditional phenotypes of dilated cardiomyopathy and left ventricular systolic failure that are associated with HIV-related heart disease are incrementally being replaced with increasing rates of diastolic dysfunction and ischemic heart disease. Moreover, recent studies have found important links between HIV-related HF and other clinical and biochemical entities, including depression, which further complicate cardiac care for PLWH. Considering these trends in the era of ART, the traditional paradigms of HIV-related cardiomyopathy and HF are being called into question, as is the therapeutic role of interventions such as ventricular assist devices and heart transplantation. In all, the mechanisms of HIV-related myocardial damage and the optimal approaches to the prevention and the treatment of cardiomyopathy and HF in PLWH remain under investigation.Keywords
This publication has 100 references indexed in Scilit:
- Peripartum cardiomyopathy coexistent with human immunodeficiency virus: A substantial obstetric jeopardyHeart Views, 2013
- The impact of HAART on cardiomyopathy among children and adolescents perinatally infected with HIV-1AIDS, 2012
- Sudden Cardiac Death in Patients With Human Immunodeficiency Virus InfectionJACC, 2012
- Pathogenesis of HIV-Associated Pulmonary Hypertension: Potential Role of HIV-1 nefProceedings of the American Thoracic Society, 2011
- Long-term outcome of Peripartum cardiomyopathy in a population with high seropositivity for Human Immunodeficiency VirusInternational Journal of Cardiology, 2011
- HIV infection is not associated with echocardiographic signs of cardiomyopathy or pulmonary hypertension among pregnant Ugandan womenInternational Journal of Cardiology, 2011
- Risk of Myocardial Infarction in Patients with HIV Infection Exposed to Specific Individual Antiretroviral Drugs from the 3 Major Drug Classes: The Data Collection on Adverse Events of Anti‐HIV Drugs (D:A:D) StudyThe Journal of Infectious Diseases, 2010
- Venous Thromboembolism in Patients With HIV/AIDSJAIDS Journal of Acquired Immune Deficiency Syndromes, 2008
- The Incidence of Pediatric Cardiomyopathy in Two Regions of the United StatesNew England Journal of Medicine, 2003
- Acute cardiotoxicity of nucleoside analogs FddA and FddI in ratsFundamental and Applied Toxicology, 1993